Insider Transactions in Q1 2024 at Johnson & Johnson (JNJ)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 09
2024
|
Jennifer L Taubert EVP, WWC. Innovative Medicine |
SELL
Open market or private sale
|
Direct |
59,397
-29.58%
|
$9,265,932
$156.27 P/Share
|
|
Feb 09
2024
|
Jennifer L Taubert EVP, WWC. Innovative Medicine |
BUY
Exercise of conversion of derivative security
|
Direct |
59,397
+22.83%
|
$5,345,730
$90.44 P/Share
|
|
Feb 08
2024
|
William Hait EVP, Chief EI and Med Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,113
-3.23%
|
$173,628
$156.33 P/Share
|
|
Feb 08
2024
|
William Hait EVP, Chief EI and Med Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,059
+8.15%
|
-
|
|
Feb 08
2024
|
Timothy Schmid EVP, WW Chair, MedTech |
SELL
Payment of exercise price or tax liability
|
Direct |
1,001
-9.15%
|
$156,156
$156.33 P/Share
|
|
Feb 08
2024
|
Timothy Schmid EVP, WW Chair, MedTech |
BUY
Exercise of conversion of derivative security
|
Direct |
1,964
+15.22%
|
-
|
|
Feb 08
2024
|
James D. Swanson EVP, CIO |
SELL
Payment of exercise price or tax liability
|
Direct |
554
-4.99%
|
$86,424
$156.33 P/Share
|
|
Feb 08
2024
|
James D. Swanson EVP, CIO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,868
+14.39%
|
-
|
|
Feb 08
2024
|
Elizabeth Forminard Executive VP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
363
-5.62%
|
$56,628
$156.33 P/Share
|
|
Feb 08
2024
|
Elizabeth Forminard Executive VP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
979
+13.16%
|
-
|
|
Feb 08
2024
|
Joseph J Wolk Exec VP, CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,047
-1.94%
|
$163,332
$156.33 P/Share
|
|
Feb 08
2024
|
Joseph J Wolk Exec VP, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,686
+6.4%
|
-
|
|
Feb 08
2024
|
Kathryn E Wengel EVP, Chief TO and Risk Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,009
-1.49%
|
$157,404
$156.33 P/Share
|
|
Feb 08
2024
|
Kathryn E Wengel EVP, Chief TO and Risk Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,971
+2.82%
|
-
|
|
Feb 08
2024
|
Joaquin Duato CEO and Chairman of the Board |
SELL
Payment of exercise price or tax liability
|
Direct |
2,269
-0.73%
|
$353,964
$156.33 P/Share
|
|
Feb 08
2024
|
Joaquin Duato CEO and Chairman of the Board |
BUY
Exercise of conversion of derivative security
|
Direct |
5,225
+1.65%
|
-
|
|
Feb 08
2024
|
Jennifer L Taubert EVP, WWC. Innovative Medicine |
SELL
Payment of exercise price or tax liability
|
Direct |
1,913
-1.33%
|
$298,428
$156.33 P/Share
|
|
Feb 08
2024
|
Jennifer L Taubert EVP, WWC. Innovative Medicine |
BUY
Exercise of conversion of derivative security
|
Direct |
3,739
+2.54%
|
-
|
|
Feb 08
2024
|
Robert J Decker VP Corporate Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
215
-1.22%
|
$33,540
$156.33 P/Share
|
|
Feb 08
2024
|
Robert J Decker VP Corporate Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
655
+3.59%
|
-
|
|
Feb 08
2024
|
Vanessa Broadhurst EVP, Global Corp Affairs |
SELL
Payment of exercise price or tax liability
|
Direct |
703
-3.33%
|
$109,668
$156.33 P/Share
|
|
Feb 08
2024
|
Vanessa Broadhurst EVP, Global Corp Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
1,880
+8.19%
|
-
|
|
Feb 08
2024
|
Peter Fasolo Exec VP, Chief HR Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
781
-0.75%
|
$121,836
$156.33 P/Share
|
|
Feb 08
2024
|
Peter Fasolo Exec VP, Chief HR Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,135
+2.0%
|
-
|